<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the present studies, we have evaluated the effects of N-[4-(2-¿[(3-Chlorophenyl)<z:chebi fb="36" ids="29309">methyl</z:chebi>]amino¿ethyl)<z:chebi fb="1" ids="30396">phenyl</z:chebi>]-2-thiophenecarbo ximidamide dihydrochloride (ARL 17477) on recombinant human neuronal NOS (nNOS) and endothelial NOS (eNOS) </plain></SENT>
<SENT sid="1" pm="."><plain>We then carried out pharmacokinetic studies and measured cortical nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (NOS) inhibition to determine that the compound crossed the blood brain barrier </plain></SENT>
<SENT sid="2" pm="."><plain>Finally, the compound was evaluated in a model of global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> in the gerbil and two models of transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> in the rat </plain></SENT>
<SENT sid="3" pm="."><plain>The IC(50) values for ARL 17477 on human recombinant human nNOS and eNOS were 1 and 17 microM, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>ARL 17477 (50 mg/kg i.p.) produced a significant reduction in the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced hippocampal damage following global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> when administered immediately post-occlusion, but failed to protect when administration was delayed until 30 min post-occlusion </plain></SENT>
<SENT sid="5" pm="."><plain>In the endothelin-1 model of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, ARL 17477 (1 mg/kg i.v.) significantly attenuated the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume when administered at either 0, 1 or 2 h post-endothelin-1 (P&lt;0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>In the intraluminal suture model, ARL 17477 at both 1 and 3 mg/kg i.v. failed to reduce the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume measured at 1, 3 or 7 days post-occlusion </plain></SENT>
<SENT sid="7" pm="."><plain>These results demonstrate that ARL 17477 protects against global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> in gerbils and provides some reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> volume following transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in rats, indicating that nNOS inhibition may be a useful treatment of ischaemic conditions </plain></SENT>
</text></document>